Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Osteoarthritis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1Cancer Pain 1Bone Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 43fludarabine phosphate 42Mycophenolic Acid 30Whole-Body Irradiation 27Cyclosporine 27Busulfan 26Tacrolimus 23Antilymphocyte Serum 23Methotrexate 20Etoposide 20romidepsin 19Filgrastim 19Melphalan 16Radiotherapy 15Flow Cytometry 15Vorinostat 13Methylprednisolone 13Brentuximab Vedotin 13Lenalidomide 12Bexarotene 12mogamulizumab 11Psychiatric Rehabilitation 11Bortezomib 11Therapeutics 10Rituximab 10Gemcitabine 10fludarabine 9Polymerase Chain Reaction 9Biopsy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Duration of Therapy × Clear all
NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Merck Sharp & Dohme LLC

Phase 2 Completed
74 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡